COST-EFFECTIVENESS ANALYSIS OF AUTOMATIC BLADDER SURVEILLANCE SYSTEM (ABSS)

[1]  Richard S. Johnston,et al.  A full-color scanning fiber endoscope , 2006, SPIE BiOS.

[2]  C. Philipp,et al.  Diagnostic potential of virtual cystoscopy of the bladder: MRI vs CT. Preliminary report , 2003, European Radiology.

[3]  A. Willan.  Statistical analysis of cost–effectiveness data from randomized clinical trials , 2006, Expert review of pharmacoeconomics & outcomes research.

[4]  E. Castle,et al.  Cost analysis of radical retropubic, perineal, and robotic prostatectomy. , 2006, Journal of endourology.

[5]  W. Kassouf,et al.  Biomarkers for detection and surveillance of bladder cancer. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[6]  L Walker,et al.  Does flexible cystoscopy miss more tumours than rod-lens examination? , 1993, British journal of urology.

[7]  Murray Krahn,et al.  Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  R. Rabin,et al.  EQ-SD: a measure of health status from the EuroQol Group , 2001, Annals of medicine.

[9]  A Briggs,et al.  Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. , 1998, Health economics.

[10]  Y. Zhang,et al.  Comparison of Surveillance Strategies for Low-Risk Bladder Cancer Patients , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[11]  E. Steyerberg,et al.  Non‐muscle‐invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost‐effective alternative? , 2009, BJU international.

[12]  C. Roelofs.  Prevention effectiveness: A guide to decision analysis and economic evaluation , 1997 .

[13]  G. Breithardt,et al.  Improving patient access to novel medical technologies in Europe. , 2006, European heart journal.

[14]  K Claxton,et al.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.

[15]  A R Willan,et al.  Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Y. Lotan,et al.  Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. , 2006, Urologic oncology.

[17]  Erik Marel,et al.  What is driving the rise in health care expenditures?: an inquiry into the nature and causes of the cost disease , 2011 .

[18]  K. Thorpe.  The rise in health care spending and what to do about it. , 2005, Health affairs.

[19]  T. Kwast,et al.  Cytology and Urinary Markers for the Diagnosis of Bladder Cancer , 2009 .

[20]  Sangtae Park,et al.  Development of an Automated Steering Mechanism for Bladder Urothelium Surveillance. , 2009, Journal of medical devices.

[21]  M. Babjuk,et al.  Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. , 2012, European urology.

[22]  Herbert Stepp,et al.  Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. , 2013, European urology.

[23]  C. Hassan,et al.  Cost‐effectiveness of Endoscopic Surveillance for Gastric Intestinal Metaplasia , 2010, Helicobacter.

[24]  M. Drummond,et al.  A rational framework for decision making by the National Institute For Clinical Excellence (NICE) , 2002, The Lancet.

[25]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.

[26]  M. Grasso.  Bladder Cancer: A Major Public Health Issue , 2008 .

[27]  Eric J. Seibel,et al.  Multimodal flexible cystoscopy for creating co-registered panoramas of the bladder urothelium , 2012, Photonics West - Biomedical Optics.

[28]  Milton C Weinstein,et al.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[29]  M. Halpern,et al.  Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean? , 2008, CA: a cancer journal for clinicians.

[30]  M. Brosa,et al.  Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[31]  C. Woodhouse,et al.  Cost-Effectiveness of Investigations for Invasive Bladder Cancer , 1987, Journal of the Royal Society of Medicine.

[32]  Uwe Siebert,et al.  Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[33]  S. Parikh,et al.  The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. , 2012, Urologic oncology.

[34]  James E. Stahl,et al.  Pharmacoeconomics 2008; 26 (2): 131-148 , 2012 .

[35]  D. Globe,et al.  Surveillance and Treatment of Non-Muscle-Invasive Bladder Cancer in the USA , 2012, Advances in urology.

[36]  Kathryn A Phillips,et al.  An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. , 2003, Pharmacogenomics.

[37]  A. Sabichi,et al.  Clinical model of lifetime cost of treating bladder cancer and associated complications. , 2006, Urology.

[38]  N. Malats,et al.  Screening for bladder cancer: a perspective , 2008, World Journal of Urology.

[39]  Maximilian Burger,et al.  Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. , 2012, The Journal of urology.

[40]  Yair Lotan,et al.  Should we screen for bladder cancer in a high‐risk population? , 2006, Cancer.

[41]  Uwe Siebert,et al.  Modeling Good Research Practices—Overview , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[42]  J. Witjes,et al.  Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer , 2014, Therapeutic advances in urology.

[43]  M. Sculpher,et al.  Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.

[44]  Steven D Pearson,et al.  Quality, innovation, and value for money: NICE and the British National Health Service. , 2005, JAMA.

[45]  M. Laniado,et al.  The nurse cystoscopist: a feasible option? , 2000, BJU international.

[46]  A. Culyer,et al.  Economic and Medical Evaluation of Health Care Technologies , 1983, Springer Berlin Heidelberg.

[47]  S. Golder,et al.  Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment , 2012, PharmacoEconomics.

[48]  N. Marcussen,et al.  Fluorescence‐guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in T  a/T1 patients: a randomized two‐centre study , 2011, BJU international.

[49]  M. Mcgrath.  Cost Effectiveness in Health and Medicine. , 1998 .

[50]  B. Geavlete,et al.  Treatment changes and long‐term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non‐muscle‐invasive bladder cancer (NMIBC)? , 2012, BJU international.

[51]  M. Drummond,et al.  Economic Evaluation in Health Care: Merging Theory with Practice , 2002 .

[52]  M. Krahn,et al.  Acute appendicitis in young children: cost-effectiveness of US versus CT in diagnosis--a Markov decision analytic model. , 2009, Radiology.

[53]  W. Whitmore,et al.  Bladder papilloma: therapeutic and cost effect of outpatient department management. , 1981, Urology.

[54]  K. Loughlin,et al.  Economic impact of tumor markers in bladder cancer surveillance. , 2008, Urology.

[55]  C. Stief,et al.  Routine Use of Photodynamic Diagnosis of Bladder Cancer: Practical and Economic Issues , 2008 .

[56]  D. Schilling,et al.  Economic aspects of bladder cancer: what are the benefits and costs? , 2009, World Journal of Urology.

[57]  H. Ozen.  Bladder cancer. , 1998, Current opinion in oncology.

[58]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[59]  M J Buxton,et al.  Modelling in economic evaluation: an unavoidable fact of life. , 1997, Health economics.

[60]  S. Shariat,et al.  Cost‐effective treatment of low‐risk carcinoma not invading bladder muscle , 2013, BJU international.

[61]  J. Jones,et al.  The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation. , 2013, The Canadian journal of urology.

[62]  Anthony J. Culyer,et al.  The NICE Cost-Effectiveness Threshold , 2012, PharmacoEconomics.

[63]  J. Witjes,et al.  The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer , 2013, World Journal of Urology.

[64]  A. Finelli,et al.  Optimal Management of High-Risk T1G3 Bladder Cancer: A Decision Analysis , 2007, PLoS medicine.

[65]  S. Donat.  Evaluation and follow-up strategies for superficial bladder cancer. , 2003, The Urologic clinics of North America.

[66]  H. Rønning,et al.  Routine use of ultrasound and flexible cystoscopy in the control of benign bladder tumours , 2007, International Urology and Nephrology.

[67]  S. Bae,et al.  International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? , 2010, Health economics.

[68]  M. Sculpher,et al.  Decision Modelling for Health Economic Evaluation , 2006 .

[69]  Andrew Briggs,et al.  An Introduction to Markov Modelling for Economic Evaluation , 1998, PharmacoEconomics.

[70]  M. Drummond,et al.  Whither trial-based economic evaluation for health care decision making? , 2006, Health economics.

[71]  R. Bristow,et al.  Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. , 2006, Gynecologic oncology.